Endometrial Cancer

Data Definitions for the National Minimum Core Data Set to support the introduction of Endometrial Cancer Quality Performance Indicators

Definitions developed by Public Health Scotland (PHS) in Collaboration with the Endometrial Quality Performance Indicator Development Group

Version 3.3: February 2021

To be used in conjunction with:
1. Endometrial Clinical Quality Performance Indicators V3.0
2. Endometrial QPI Dataset Validations (Latest Published Version).
3. Endometrial Measurability of Quality Performance Indicators (Latest Published Version)
**Title** | Endometrial – Data Definitions for Minimum Core Dataset for Quality Performance Indicators (QPIs)
---|---
**Date Published/Issued** | February 2021
**Date Effective From** | October 2018
**Version/Issue Number** | V3.3
**Document Type** | Guidance
**Document Status** | Final
**Standard Audience** | NHS staff involved in implementing and recording Endometrial Quality Performance Indicators.
**Cross References** | Endometrial Quality Performance Indicators
Endometrial Measurability of Quality Performance Indicators
**Author** | Public Health Scotland (PHS)

**Revision History**

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Summary of Changes</th>
<th>Name</th>
<th>Changes Marked</th>
</tr>
</thead>
<tbody>
<tr>
<td>V1.1</td>
<td>March 2015</td>
<td>Changes agreed out with review during validation QA to support data collection.</td>
<td>Jane Garrett</td>
<td>See page vi</td>
</tr>
<tr>
<td>V2.0</td>
<td>July 2015</td>
<td>Changes agreed at 9mth Review</td>
<td>Jane Garrett</td>
<td>See page vi</td>
</tr>
<tr>
<td>V2.1</td>
<td>September 2016</td>
<td>Changes agreed at Baseline Review</td>
<td>Charlotte Anthony</td>
<td>See page v</td>
</tr>
<tr>
<td>V2.2</td>
<td>July 2017</td>
<td>Changes outwith review</td>
<td>Charlotte Anthony</td>
<td>See page v</td>
</tr>
<tr>
<td>V2.3</td>
<td>October 2017</td>
<td>Changes outwith review</td>
<td>Charlotte Anthony</td>
<td>See page v</td>
</tr>
<tr>
<td>V2.4</td>
<td>October 2017</td>
<td>Changes outwith review</td>
<td>Karen Heatlie</td>
<td>See page v</td>
</tr>
<tr>
<td>V2.5</td>
<td>November 2018</td>
<td>Changes agreed out with review during validation QA to support data collection.</td>
<td>Jane Garrett</td>
<td>See page v</td>
</tr>
<tr>
<td>Version</td>
<td>Date</td>
<td>Summary of Changes</td>
<td>Name</td>
<td>Changes Marked</td>
</tr>
<tr>
<td>---------</td>
<td>--------------</td>
<td>---------------------------------------------------------</td>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>V3.0</td>
<td>January 2019</td>
<td>Changes agreed at Formal Review</td>
<td>Jane Garrett</td>
<td>See page iv</td>
</tr>
<tr>
<td>V3.1</td>
<td>November 2019</td>
<td>Changes outwith review</td>
<td>Caroline Dawson</td>
<td>See page iii</td>
</tr>
<tr>
<td>V3.2</td>
<td>May 2020</td>
<td>Addition to dataset during COVID 19 Pandemic and changes agreed outwith review</td>
<td>Jane Garrett</td>
<td>See page iii</td>
</tr>
<tr>
<td>V3.3</td>
<td>February 2021</td>
<td>Rebranding Update</td>
<td>Ruth McPherson</td>
<td>Throughout Document</td>
</tr>
</tbody>
</table>
PREFACE

Following the publication of Better Cancer Care: An Action Plan in October 2008, the Scottish Government established the Scottish Cancer Taskforce to oversee its implementation. The NHS Scotland Healthcare Quality Strategy in 2010 expands on this by articulating quality ambitions. A quality measurement framework has been developed setting out measures and targets which will be used to monitor, challenge, manage and report progress. Part of this strategy is the development of quality performance indicators (QPIs) to drive quality improvement in cancer care throughout NHS Scotland.

As high quality data are required to enable comparisons over time and between regions, it is important that national data definitions are used to facilitate consistent data collection. National data definitions already in use have been used as much as possible to allow electronic data capture, thereby minimising duplication of data collection. Where national data definitions do not already exist, definitions used in other systems have been incorporated.

To ensure that findings are comparable across Scotland, the national dataset and data definitions in conjunction with the final quality performance indicators were agreed through public engagement and are now ready for implementation for patients diagnosed from 1st October 2014.
NOTES FOR IMPLEMENTATION OF CHANGES

The following changes should be implemented for all patients who are diagnosed with endometrial cancer on or after 1st October 2015, who are eligible for inclusion in the Endometrial cancer audit.

Changes to definitions fall into the following categories:

- to address problems with ongoing audit and standardise data definitions, where feasible, between different cancer sites
- to address problems with existing definitions
- to allow Quality Performance Indicators to be measured and reported against

General Enquiries on the Collection of the Minimum Core Data Set
If you have difficulties in using individual definitions within this document, or any comments on the attached data definitions, Public Health Scotland would welcome your feedback. Please contact: phs.canceraudit@phs.scot

CONVENTIONS

The layout for each item is standard as shown below where it is applicable:

Common Name(s):
Main Source of Data Item Standard:
Definition:
Field Name:
Field Type:
Field Length:
Notes for Users:
Codes and Values:
Related Data Item(s):

In addition the following two conventions have been used in the document:

- {curly brackets} - definition relates to one specific named data set
- 'described elsewhere' - indicates there is a definition for the named item within this document
REVISIONS TO DATASET

The following changes have been made to facilitate the recording of data.

Rebranding Updates (February 2021)

Key Information – Author amended from Information Services Division (ISD) to Public Health Scotland (PHS)

Addition to dataset during COVID 19 Pandemic (May 2020)

Database Specification

Date of Referral - add new Data item, Field Name: REFERDATE, Field Type: Date (DD/MM/CCYY), Field Length: 10

COVID 19 Impact - add new Data item, Field Name: COVID, Field Type: Integer, Field Length: 2

Dataset

Date of Referral - add new data item - implement from 1 March 2020

COVID 19 Impact - add new Data item – implemented from 1 October 2019

Revisions to Dataset outwith Review (May 2020)

Date of Diagnosis {Cancer} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’

Date Imaging Completed - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’; amend ‘10/10/1010’ to ‘10/10/1900’

Date Discussed by Care Team - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’; amend ‘10/10/1010’ to ‘10/10/1900’

Type of First Cancer Treatment – Codes and Values table remove leading ‘0’

Surgery Performed - Codes and Values table remove leading ‘0’

Surgical Approach - Codes and Values table remove leading ‘0’

Radiotherapy Course Type - Codes and Values table remove leading ‘0’

Vaginal Vault Brachytherapy {Endometrial Cancer} - Codes and Values table remove leading ‘0’
Type of Systemic Anti-Cancer Therapy (SACT) 1-2 - Codes and Values table remove leading ‘0’

Patient Entered into Clinical Trial - Codes and Values table remove leading ‘0’

Date of First Cancer treatment - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’; amend ‘10/10/1010’ to ‘10/10/1900’

Date of Definitive Treatment - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’; amend ‘10/10/1010’ to ‘10/10/1900’

Date of Surgery - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’; amend ‘10/10/1010’ to ‘10/10/1900’

Date Treatment Started (Radiotherapy) - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’; amend ‘10/10/1010’ to ‘10/10/1900’

Date Treatment Completed (Radiotherapy) - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’; amend ‘10/10/1010’ to ‘10/10/1900’

Date treatment Started Systemic Anti-Cancer Therapy (SACT) {Cancer} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’; amend ‘10/10/1010’ to ‘10/10/1900’

Date treatment Completed Systemic Anti-Cancer Therapy (SACT) {Cancer} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’; amend ‘10/10/1010’ to ‘10/10/1900’

Date of Death - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’; amend ‘10/10/1010’ to ‘10/10/1900’

Revisions to Dataset following Changes outwith Review (November 2018)

Morphology of Tumour - Pre-operative Biopsy – Codes and Values Table add code 8930/3 Endometrial Stromal Sarcoma - High Grade

Revisions to Dataset following Formal Review (January 2019)

Tumour Grade – Pre Operative Biopsy {Endometrial Cancer} - Notes for Users remove Required for QPI: ‘2’

Date of First Cancer Treatment – Notes for Users remove ‘Required for QPI: 1,’ add ‘Where this has subsequently been confirmed at MDT, the date of MDT should be recorded’
Date of Definitive Treatment {Endometrial Cancer} – Notes for Users add Required for QPI: ‘1’; add ‘Where this has subsequently been confirmed at MDT, the date of MDT should be recorded’

Date of Surgery - Notes for Users add Required for ‘QPIs: 4, 7 and for’; replace ‘and’ with ‘/’

Surgery Performed - Notes for Users add Required for QPI: ‘7’

Radiotherapy Course Type - Notes for Users add Required for QPI: ‘5’; replace ‘Required’ with ‘and’; replace ‘and’ with ‘/’

Date Treatment Started – Notes for Users remove ‘Required for QPI(s):’

Date Treatment Completed (Radiotherapy) - Notes for Users remove ‘Required for QPI(s):’

Date of Death - Notes for Users add Required for ‘QPI: 7 and for’; replace ‘and’ with ‘/’

Revisions to Dataset Outwith Review (November 2018)

Morphology of Tumour - Pre-operative Biopsy – Codes and Values table add ‘8888/8 Negative Pathology’; Main Source of Data Item Standard amend to ‘tumours of the female reproductive organs’

Morphology of Tumour - Post-operative – Codes and Values table remove ‘8010/2 Carcinoma in situ, NOS’; Main Source of Data Item Standard amend to ‘tumours of the female reproductive organs’

Type of Systemic Anti-Cancer Therapy (SACT) 1-2 – Explanatory Notes Remove Mirena coil

Revisions to Dataset Outwith Review (October 2017)

Morphology of Tumour – Post-Operative – Codes and Values table add Morphology code 8010/2 Carcinoma in situ, and 8933/3 Adenosarcoma amend Morphology code 8323/3 to read ‘Mixed Cell Adenocarcinoma

Revisions to Dataset Outwith Review (September 2017)

Person Family Name (at Diagnosis) – link updated

Person Given Name – link updated

Patient Postcode at Diagnosis {Cancer} – link updated

Date of Birth – link updated
Morphology of Tumour – Pre-Operative Biopsy – Codes and Values
Table add Morphology Codes 8010/2 Carcinoma in situ, and 8933/3 Adenosarcoma. and amend 8323/3 to read ‘Mixed Cell Adenocarcinoma

Revisions to Dataset Outwith Review (July 2017)

Surgical Approach – Codes and Values table add 03 Vaginal Hysterectomy.

Revisions to Dataset from Baseline Review (September 2016)

Type of First Cancer Treatment – Notes for Users add Insertion of intrauterine devices (IUDs) e.g. Mirena should not be considered as treatment.

Date of Definitive Treatment {Endometrial Cancer} – Notes for Users Insertion of intrauterine devices (IUDs) e.g. Mirena should not be considered as treatment.

Surgery Performed – Notes for Users add where a patient has undergone a previous bilateral salpingo-oophorectomy, the current surgery should be coded as either 01, 02 or 03 depending on the other elements of surgery performed.

Revisions to Dataset following 9 month Review (July 2015)

Date Imaging Completed (Pre-treatment) - Title remove Pre-treatment

Morphology of Tumour – Pre-Operative Biopsy – Codes and Values table add code ‘6666/6 for ‘Suspicious of cancer’, and amend adenoma to adenosarcoma

Morphology of Tumour – Post-Operative - Change adenoma to adenosarcoma

Dataset Specification

Date Imaging Completed (Pre-treatment) – Title remove Pre-treatment

Revisions to Dataset Outwith Review (March 2015)

Date of Definitive Treatment {Endometrial Cancer} - Footnote referenced

Dataset Specification

Surgery Performed – Field Length amend to 2
CRITERIA FOR INCLUSION OF PATIENTS IN AUDIT

To facilitate national comparisons the same patients must be audited throughout Scotland. The following eligibility criteria have been documented for this purpose.

Include:
- Primary endometrial cancer (including: endometrioid, carcinosarcoma, papillary serous and clear cell carcinomas) (ICD-10 C54)

Exclude:
- Pre-cancerous conditions including: cervical intra-epithelial neoplasia (CIN) and glandular intra-epithelial neoplasia (GIN)
- Patients with metastatic endometrial cancer from another primary cancer site
- Patients where the origin of the primary is uncertain
- Patients with neuroendocrine carcinomas or uterine leiomyosarcoma
- Patients with tumour type sarcoma or lymphoma
- Patients with recurrent disease (as opposed to a new primary)
- Patients with carcinoma in situ
- Patients, at date of diagnosis, under 16 years of age i.e. up to 15 years 364 days.
- Patients where the only record of their cancer is from a death certificate (DCO).
- Patients with normal residence outwith Scotland.
- Patients whose definitive cancer treatment was privately funded or undertaken outwith NHS Scotland.

NB:
- Only treatments as part of the initial treatment plan should be recorded.
- Patients treated within 6 months of a patient initially refusing further investigation can also be recorded.
DOWNLOAD FORMAT
To assist with downloading data to PHS for the National Quality Assurance Programme and other agreed activities, all sites should be able export data according to the following specification.

DATABASE SPECIFICATION

<table>
<thead>
<tr>
<th>Data Item</th>
<th>Field Name</th>
<th>Field Type</th>
<th>Size</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section 1: Demographic Items</strong></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Person Family Name (at Diagnosis)</td>
<td>PATSNAME</td>
<td>Characters</td>
<td>35</td>
<td>2</td>
</tr>
<tr>
<td>Person Given Name</td>
<td>PATFNAME</td>
<td>Characters</td>
<td>35</td>
<td>2</td>
</tr>
<tr>
<td>Patient Postcode at Diagnosis</td>
<td>PATPCODE</td>
<td>Characters</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Date of Birth</td>
<td>DOB</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>CHI Number</td>
<td>CHINUM</td>
<td>Characters</td>
<td>10</td>
<td>6</td>
</tr>
<tr>
<td><strong>Section 2: Pre-treatment Imaging and Staging Investigations</strong></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Date of Referral</td>
<td>REFERDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Location of Diagnosis (Cancer)</td>
<td>HOSP</td>
<td>Characters</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>Date of Diagnosis (Cancer)</td>
<td>DIAGDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Date Imaging Completed</td>
<td>SINVESTDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>WHO/ECOG Performance Status</td>
<td>PSTATUS</td>
<td>Integer</td>
<td>1</td>
<td>12</td>
</tr>
<tr>
<td>Date Discussed by Care Team (MDT)</td>
<td>MDTDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>COVID 19 Impact</td>
<td>COVID</td>
<td>Integer</td>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td>Morphology of Tumour – Pre-Operative Biopsy</td>
<td>BIOMORPHOL</td>
<td>Characters</td>
<td>6</td>
<td>15</td>
</tr>
<tr>
<td>Tumour Grade – Pre-Operative Biopsy (Endometrial Cancer)</td>
<td>BIOTGRADE</td>
<td>Characters</td>
<td>4</td>
<td>17</td>
</tr>
<tr>
<td>Type of First Cancer Treatment</td>
<td>FIRSTTREATMODE</td>
<td>Integer</td>
<td>2</td>
<td>18</td>
</tr>
<tr>
<td>Date of First Cancer Treatment</td>
<td>FIRSTTREATDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>19</td>
</tr>
<tr>
<td>Date of Definitive Treatment (Endometrial Cancer)</td>
<td>DEFTREATDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td><strong>Section 3: Surgery</strong></td>
<td></td>
<td></td>
<td></td>
<td>21</td>
</tr>
<tr>
<td>Location Code (Cancer Surgery)</td>
<td>HOSPSURG</td>
<td>Characters</td>
<td>5</td>
<td>22</td>
</tr>
<tr>
<td>Date of Surgery</td>
<td>SURGDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>24</td>
</tr>
<tr>
<td>Surgery Performed</td>
<td>SURG</td>
<td>Integer</td>
<td>2</td>
<td>25</td>
</tr>
<tr>
<td>Surgical Approach</td>
<td>SURGAPPR</td>
<td>Characters</td>
<td>3</td>
<td>26</td>
</tr>
<tr>
<td><strong>Section 4: Pathological Details</strong></td>
<td></td>
<td></td>
<td></td>
<td>27</td>
</tr>
<tr>
<td>Data Item</td>
<td>Field Name</td>
<td>Field Type</td>
<td>Size</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------</td>
<td>------------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Morphology of Tumour – Post-Operative</td>
<td>MORPHOL</td>
<td>Characters</td>
<td>6</td>
<td>28</td>
</tr>
<tr>
<td>Final FIGO Stage {Endometrial Cancer}</td>
<td>FIGO</td>
<td>Characters</td>
<td>5</td>
<td>30</td>
</tr>
<tr>
<td>Tumour Grade – Post Operative {Endometrial Cancer}</td>
<td>TGRADE</td>
<td>Characters</td>
<td>4</td>
<td>31</td>
</tr>
<tr>
<td><strong>Section 5: Oncology</strong></td>
<td></td>
<td></td>
<td></td>
<td>32</td>
</tr>
<tr>
<td>Radiotherapy Course Type</td>
<td>RADIOTYPE</td>
<td>Integer</td>
<td>2</td>
<td>33</td>
</tr>
<tr>
<td>Date Treatment Started (Radiotherapy)</td>
<td>RSTARTDATE</td>
<td>Date</td>
<td>10</td>
<td>34</td>
</tr>
<tr>
<td>Date Treatment Completed (Radiotherapy)</td>
<td>RCOMPDATE</td>
<td>Date</td>
<td>10</td>
<td>35</td>
</tr>
<tr>
<td>Vaginal Vault Brachytherapy {Endometrial Cancer}</td>
<td>BRACHY</td>
<td>Integer</td>
<td>2</td>
<td>36</td>
</tr>
<tr>
<td>Type of Systemic Anti-Cancer Therapy (SACT) 1-2</td>
<td>CHEMTYPE1</td>
<td>Integer</td>
<td>2</td>
<td>37</td>
</tr>
<tr>
<td>Type of Systemic Anti-Cancer Therapy (SACT) 1-2</td>
<td>CHEMTYPE2</td>
<td>Integer</td>
<td>2</td>
<td>37</td>
</tr>
<tr>
<td>Date Treatment Started Systemic Anti-Cancer Therapy (SACT) 1-2</td>
<td>CHEMDATE1</td>
<td>Date</td>
<td>10</td>
<td>39</td>
</tr>
<tr>
<td>Date Treatment Started Systemic Anti-Cancer Therapy (SACT) 1-2</td>
<td>CHEMDATE2</td>
<td>Date</td>
<td>10</td>
<td>39</td>
</tr>
<tr>
<td>Date Treatment Completed Systemic Anti-Cancer Therapy (SACT) 1-2</td>
<td>CHEMENDATE1</td>
<td>Date</td>
<td>10</td>
<td>40</td>
</tr>
<tr>
<td>Date Treatment Completed Systemic Anti-Cancer Therapy (SACT) 1-2</td>
<td>CHEMENDATE2</td>
<td>Date</td>
<td>10</td>
<td>40</td>
</tr>
<tr>
<td><strong>Section 6: Clinical Trials</strong></td>
<td></td>
<td></td>
<td></td>
<td>41</td>
</tr>
<tr>
<td>Patient Entered into Clinical Trial</td>
<td>TRIAL</td>
<td>Integer</td>
<td>2</td>
<td>42</td>
</tr>
<tr>
<td><strong>Section 7: Death Details</strong></td>
<td></td>
<td></td>
<td></td>
<td>43</td>
</tr>
<tr>
<td>Date of Death</td>
<td>DOD</td>
<td>Date</td>
<td>10</td>
<td>44</td>
</tr>
</tbody>
</table>
Section 1: Demographic Items
Person Family Name (at Diagnosis)

Common Name(s): Surname, Family name

Main Source of Data Item Standard: Government Data Standards Catalogue

Definition:
That part of a person's name which is used to describe family, clan, tribal group, or marital association at the time of diagnosis.

Field Name: PATSNAME
Field Type: Characters
Field Length: 35

Notes for Users:
The surname of a person represents that part of the name of a person indicating the family group of which the person is part.
It should be noted that in Western culture this is normally the latter part of the name of a person. However, this is not necessarily true of all cultures. This will, of course, give rise to some problems in the representation of the name. This is resolved by including the data item Name Element Position in the structured name indicating the order of the name elements.

From SMR Definitions and Codes

Notes by Users:
Person Given Name

Common Name(s): Forename, Given Name, Personal Name

Main Source of Data Item Standard of Standard: Government Data Standards Catalogue

Definition: The forename or given name of a person.

Field Name: PATFNAME
Field Type: Characters
Field Length: 35

Notes for Users:
The first forename of a person represents that part of the name of a person which after the surname is the principal identifier of a person.

Where the person's preferred forename is not the first forename, the related data item 'Preferred Forename' should be used to indicate this.

Notes by Users:
Patient Postcode at Diagnosis

Main Source of Data Item Standard: Government Data Standards Catalogue

Definition: Postcode of patient's usual place of residence on the date of diagnosis

Field Name: PATPCODE
Field Type: Characters
Field Length: Maximum 8

Notes for Users: Postcode is included in BS7666 Address (GDSC) but there is also a separate Post Code standard which will be populated from BS7666 Address Post Code.

This item can be derived from the date of diagnosis and patient address at that time

Related Data Item(s): Date of Diagnosis

Notes by Users:
Date of Birth

Main source of Data Item Standard: Government Data Standards Catalogue

Definition: The date on which a person was born or is officially deemed to have been born, as recorded on the Birth Certificate.

Field Name: DOB
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users:
If the patient's date of birth is recorded differently on different occasions, the most frequently used or latest date should be recorded.

The patient's full date of birth inclusive of the century should be recorded. The format should be DD/MM/CCYY e.g. 01/02/2011.

Related Data Item(s):
CHI Number

Notes by Users:
CHI Number

Main Source of Data Item Standard of Standard: Scottish Executive Health Department.

Definition: The Community Health Index (CHI) is a population register, which is used in Scotland for health care purposes. The CHI number uniquely identifies a person on the index.

Field Name: CHINUM
Field Type: Characters
Field Length: 10

Notes for Users:
The Community Health Index (CHI) is a computer based population index whose main function at present is to support primary care services. CHI contains details of all Scottish residents registered with a General Practitioner and was originally envisaged and implemented as a population-based index to help assess the success of immunisation and screening programmes. It is therefore closely integrated with systems for child health, cervical cytology and breast screening call and recall. It is intended that this number, the Scottish equivalent of the new NHS number in England and Wales, should become the Unique Patient Identifier throughout the NHS in Scotland.

From Designed to Care - Scottish Office

The CHI number is a unique numeric identifier, allocated to each patient on first registration with the system. The CHI number is a 10-character code consisting of the 6-digit date of birth (DDMMYY), two digits, a 9th digit which is always even for females and odd for males and an arithmetical check digit.

(PhS, NHS National Services Scotland)

The CHI number should always be used to identify a patient. However, Health record identifiers, such as hospital numbers in Patient Administration Systems (PAS), may be used locally, in conjunction with the CHI number or in the absence of the CHI number, to track patients and their records.

Although there may be no number when a patient presents for treatment, there must be an allocation at some point in the episode of care as CHI is mandatory on all clinical communications.

Non-Scottish patients and other temporary residents can have a CHI number allocated if required but it is envisaged that future development may allow the identifying number used in other UK countries to be used in Scotland.

Related Data Item(s):
Date of Birth

Notes by Users:
Section 2: Pre-treatment Imaging and Staging Investigations
Date of Referral

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The date on which the patient referral to secondary care for the investigation and / or treatment of Endometrial cancer was received.

**Field Name:** REFERDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:** Required for national survival analysis and national comparative analysis.

The referral date is the date of receipt of initial referral into secondary care.

Where referral is through a screening programme, referral date is the date a request for further diagnostic intervention is received.

Where presentation is via A & E or other direct referral to hospital the referral date is the date the patient presents to hospital.

If the exact date is not documented, record as 09/09/1900.

**Notes by Users:**
Location of Diagnosis {Cancer}

Main Source of Data Item Standard: The National Audit Cancer Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The patient's hospital of investigation in which the diagnosis of cancer was first made.

Field Name: HOSP
Field Type: Characters
Field Length: 5

Notes for Users: Required for analysis purposes and clarifying responsibility for data collection.

Details of location codes for hospitals can be found in the "Definitions and Codes for the NHS in Scotland" manual produced by PHS.

Location codes for hospitals are five character codes maintained by PHS and the General Register Office (Scotland). The first character denotes the health board, the next three are assigned and the fifth denotes the type of location (H=hospital) e.g.

A111H=Crosshouse Hospital
G107H=Glasgow Royal Infirmary
X9999=Not recorded

If a patient was provisionally diagnosed at one hospital but transferred to another for confirmation of the diagnosis only e.g. biopsy, then returns to the original hospital, the first hospital should be recorded as the Location of diagnosis.

Codes and Values:

Related Data Items:
Date of Diagnosis {Cancer}

Notes by Users:
Date of Diagnosis {Cancer}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date on which the cancer was first diagnosed whether by histology, cytology, immunology, cytogenetics or clinical (including radiological) methods.

Field Name: DIAGDATE
Field Type: Date (DD/MM/CCYY)
Field length: 10

Notes for Users: Required for national survival analysis and national comparative analysis.

The date recorded is the date of the first investigative procedure that confirms a diagnosis of endometrial cancer.

If the exact date is not documented, record as 09/09/1900.

The date recorded is the date the procedure was performed, not the date the report was issued.

Codes and Values:

Related Data Items:
Location of Diagnosis {Cancer}

Notes by Users:
Date Imaging Completed

Main Source of Data Item Standard: The National Audit Cancer Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date abdomen and pelvis imaging investigations were completed by computed tomography (CT) or magnetic resonance imaging (MRI).

Field Name: SINVESTDATE
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users: Required for QPI: 1

Several investigations may be undertaken prior to staging. As a minimum a CT or MRI of the abdomen AND pelvis should be completed before definitive treatment commences.

These investigations may be done separately and at different times and may be a combination of CT and MRI. Record the date that ALL items are complete, e.g. if CT abdomen and MRI pelvis done on separate days then record the final date.

If CT or MRI of abdomen and pelvis was not completed or if only one component was completed then record as not applicable (10/10/1900).

If the exact date is not documented, record as (09/09/1900).

Related data item(s):

Notes by Users:
WHO/ ECOG Performance Status

Main Source of Data Item Standard: WHO (World Health Organisation) and ECOG (Eastern Cooperative Oncology Group)


Field Name: PSTATUS
Field Type: Integer
Field length: 1

Notes for Users: Required for national survival analysis and national comparative analysis.

The WHO/ECOG performance status is a grade on a five point scale (range 0 to 4) at the time of investigation in which ‘0’ denotes normal activity and ‘4’ a patient who is 100% bedridden. If it is not documented do not deduce from other information and record as ‘Not recorded’.

This item may occur more than once throughout a patient’s record.

This field relates to pre-treatment performance status i.e. at the time of the MDT closest to actual treatment.
If the performance status falls between two scores, record the higher value i.e. the worst performance status.

Codes and values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Fully active, able to carry on all pre-disease performance without restriction</td>
</tr>
<tr>
<td>1</td>
<td>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light housework, office work</td>
</tr>
<tr>
<td>2</td>
<td>Ambulatory and capable of self care but unable to carry out any work activities: up and about more than 50% of waking hours</td>
</tr>
<tr>
<td>3</td>
<td>Capable of only limited self care, confined to bed or chair more than 50% of waking hours</td>
</tr>
<tr>
<td>4</td>
<td>Completely disabled, cannot carry on any self care, totally confined to bed or chair</td>
</tr>
<tr>
<td>9</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>

Data Definitions for the National Minimum Core Dataset for Endometrial Cancer
Developed by ISD Scotland, 2014
12
Date Discussed by Care Team (MDT)

Common name: Date discussed by multidisciplinary team (MDT) {Cancer}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This denotes the date the care team meeting was held to discuss the management of the patient's care.

Field Name: MDTDATE  
Field Type: Date (DD/MM/CCYY)  
Field Length: 10

Notes for Users: Required for QPI: 2

A cancer multidisciplinary care team may include surgeons, oncologists, radiologists, pathologists, nurses, physiotherapists and others relevant to the treatment of a specific cancer. The team meets on a regular basis to discuss optimal patient management. Documentation of the discussion should be included in the case-note or other formal documentation.

The first MDT meeting date will be recorded.

If the patient has not been discussed by the MDT record as 10/10/1900 (Not applicable).

If the date of the MDT meeting is unknown record as 09/09/1900 (Not recorded)

Related data Item(s):
COVID 19 Impact

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: A record of whether COVID 19 has impacted on treatment decisions.

Field Name: COVID
Field Type: Integer
Field Length: 2

Notes for Users: Required for national survival analysis and national comparative analysis.

The COVID 19 pandemic will have an impact on the patient pathways of some patients, potentially affecting the treatment they will receive. This may affect treatment decisions from the outset or plans may change part way through treatment. MDTs will record when the recommendations of the MDT for management are made on the basis of emergency COVID 19 management guideline and differ from what would otherwise be advised.

Where there is a record of a patients treatment being amended due to the emergency COVID 19 management guidelines elsewhere, for example amendments to treatment after MDT discussion, then this can also be recorded under ‘Yes – other’, however it is acknowledged that this information may not be complete.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes - plan developed by MDT</td>
<td>MDT record treatment as determined by emergency COVID 19 management guidelines from the outset</td>
</tr>
<tr>
<td>2</td>
<td>Yes - plan amended by MDT</td>
<td>MDT record amendment to existing treatment plan due to emergency COVID 19 management guidelines</td>
</tr>
<tr>
<td>3</td>
<td>Yes – Other</td>
<td>Other record of amendment to treatment due to emergency COVID 19 management guidelines e.g. clinic letter about alteration of treatment plan</td>
</tr>
<tr>
<td>4</td>
<td>No</td>
<td>No evidence of patient treatment being affected by COVID 19</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td>Where documentation of part of the patient pathway is unavailable, e.g. for patients diagnosed outwith NHS Scotland, or where the patient moves away while treatment is still ongoing</td>
</tr>
</tbody>
</table>
Morphology of Tumour – Pre-Operative Biopsy

Main Source of Data Item Standard: Pathology and Genetics of Tumours of the Female Reproductive Organs, WHO Histological Classification of Tumours 2007.

Definition: This is the morphology of the tumour according to the International Classification of Diseases for Oncology (ICD-O(3)) based on the pre-operative biopsy.

Field Name: BIOMORPHOL
Field Type: Characters
Field Length: 6

Notes for Users: Required for QPIs: 1, 2

The morphology terms have five-digit code numbers which run from 8000/0 to 9989/1; the first four digits indicate the specific histologic terms and the fifth digit, after the slash, is a behaviour code.

If material supplied cannot be assessed code to ‘not assessable’ (1111/1).

If not recorded, record as 9999/9 (Not recorded).

If no biopsy diagnostic procedures were undertaken prior to definitive operation record as not applicable (1010/0).

Morphology codes are shown below. This list is not exhaustive and if a code is not on the list please contact - phs.canceraudit@phs.scot for advice.
<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>8010/2</td>
<td>Carcinoma in situ, NOS</td>
</tr>
<tr>
<td>8010/3</td>
<td>Carcinoma, NOS, epithelial tumour, malignant</td>
</tr>
<tr>
<td>8020/3</td>
<td>Carcinoma, undifferentiated, NOS</td>
</tr>
<tr>
<td>8050/3</td>
<td>Papillary carcinoma, NOS</td>
</tr>
<tr>
<td>8070/3</td>
<td>Squamous cell carcinoma</td>
</tr>
<tr>
<td>8120/3</td>
<td>Transitional cell carcinoma</td>
</tr>
<tr>
<td>8140/3</td>
<td>Adenocarcinoma, NOS</td>
</tr>
<tr>
<td>8262/3</td>
<td>Villous adenocarcinoma</td>
</tr>
<tr>
<td>8310/3</td>
<td>Clear cell adenocarcinoma, clear cell carcinoma</td>
</tr>
<tr>
<td>8323/3</td>
<td>Mixed Cell Adenocarcinoma</td>
</tr>
<tr>
<td>8380/3</td>
<td>Endometrioid adenocarcinoma, endometrioid carcinoma, endometrioid cystadenocarcinoma</td>
</tr>
<tr>
<td>8382/3</td>
<td>Endometrioid adenocarcinoma, secretory variant</td>
</tr>
<tr>
<td>8383/3</td>
<td>Endometrioid adenocarcinoma, ciliated cell variant</td>
</tr>
<tr>
<td>8441/3</td>
<td>Serous cystadenocarcinoma, serous adenocarcinoma, serous carcinoma</td>
</tr>
<tr>
<td>8480/3</td>
<td>Mucinous adenocarcinoma</td>
</tr>
<tr>
<td>8481/3</td>
<td>Mucin-producing (or secreting) adenocarcinoma, mucin-producing (or secreting) carcinoma</td>
</tr>
<tr>
<td>8570/3</td>
<td>Endometrioid adenocarcinoma with squamous differentiation</td>
</tr>
<tr>
<td>8041/3</td>
<td>Small cell carcinoma</td>
</tr>
<tr>
<td>8560/3</td>
<td>Adenosquamous carcinoma</td>
</tr>
<tr>
<td>8980/3</td>
<td>Carcinosarcoma, NOS</td>
</tr>
<tr>
<td>8930/3</td>
<td>Endometrial Stromal Sarcoma - High Grade</td>
</tr>
<tr>
<td>8933/3</td>
<td>Adenosarcoma</td>
</tr>
<tr>
<td>7777/7</td>
<td>Atypical Hyperplasia</td>
</tr>
<tr>
<td>6666/6</td>
<td>Suspicious of cancer</td>
</tr>
<tr>
<td>8888/8</td>
<td>Negative Pathology</td>
</tr>
<tr>
<td>1111/1</td>
<td>Not assessable</td>
</tr>
<tr>
<td>1010/0</td>
<td>Not applicable</td>
</tr>
<tr>
<td>9999/9</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>

Related Data Items:
Tumour Grade – Pre-Operative Biopsy {Endometrial Cancer}

**Definition:** The pathological assessment of tumour differentiation used as a prognostic indicator. This is the tumour grade based on the pre-operative biopsy.

**Field Name:** BIOTGRADE  
**Field Type:** Characters  
**Field length:** 4

**Notes for Users:** Required for QPI: 1

The pathology report should state grade as high, moderate or low. If there are mixed statements (e.g. low to moderate grade) record the worst situation (moderate in this example).

If grade is not documented do not deduce from other information and record as ‘not recorded’.

If no biopsy diagnostic procedures were undertaken prior to definitive operation record as not applicable (96).

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>Low Grade</td>
<td>Well differentiated</td>
</tr>
<tr>
<td>G2</td>
<td>Moderate Grade</td>
<td>Moderately differentiated</td>
</tr>
<tr>
<td>G3</td>
<td>High Grade</td>
<td>Poorly differentiated, undifferentiated</td>
</tr>
<tr>
<td>8888</td>
<td>Not assessable</td>
<td>Grade cannot be determined, e.g. specimen too poorly preserved or too small. Includes microinvasion.</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>e.g. no biopsy performed, negative pathology</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

**Related Data Item(s):**
Type of First Cancer Treatment

Common name: Mode of first treatment

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This denotes the first specific treatment modality administered to a patient.

Field Name: FIRSTTREATMODE
Field Type: Integer
Field length: 2

Notes for Users: Required for national survival analysis and national comparative analysis.

For any particular modality it is the first treatment and not specifically the definitive treatment i.e. this does not include purely diagnostic biopsies such as incisional biopsies, needle biopsies or core biopsies.

Insertion of intrauterine devices (IUDs) e.g. Mirena should not be considered as treatment.

Record patients as having ‘supportive care only’ if a decision was taken not to give the patient any active treatment as part of their primary therapy. No active treatment includes watchful waiting and supportive care but not palliative chemotherapy and/or radiotherapy.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Explanatory</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Radiotherapy</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Chemotherapy</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Biological therapy</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Endoscopic</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Chemoradiotherapy</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Supportive care</td>
<td>No active treatment</td>
</tr>
<tr>
<td>12</td>
<td>Watchful waiting</td>
<td>No active treatment</td>
</tr>
<tr>
<td>11</td>
<td>Other therapy</td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>Patient died before treatment</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Patient refused all therapies</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Item(s):
Date of First Cancer Treatment
Date of First Cancer Treatment

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This denotes the date the type of first cancer treatment was given to the patient.

Field Name: FIRSTTREATDATE
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users:

This field should be recorded for all patients including those with supportive care only (‘No active treatment’) (see below).

If type of first cancer treatment is ‘Supportive care only’ or ‘Watchful waiting’, the date recorded should be the first date the decision was taken not to give the patient treatment as part of their primary therapy. Where this has subsequently been confirmed at MDT, the date of MDT should be recorded. The aim of this date is to distinguish between patients who have initially had no treatment but receive some therapy when symptoms develop.

The date recorded should be that of the first type of cancer treatment.

If the exact date is not documented, record as 09/09/1900 (Not recorded).

If the patient died before treatment or the patient refused treatment, record as 10/10/1900 (Not applicable).

Related Data Item(s):
Type of First Cancer Treatment
Date of Definitive Treatment {Endometrial Cancer}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This denotes the date definitive cancer treatment was given to the patient.

Field Name: DEFTREATDATE
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users: Required for QPIs: 1, 2

For patients with Endometrial cancer definitive treatment may be:
- Surgical resection
- Radiotherapy,
- Chemotherapy or
- Hormonal therapy.

If a patient has more than one of those treatments listed the first should be recorded.

For patients who receive hormonal therapy with no further treatment, it is the start date of hormone therapy which should be recorded. For patients who receive hormone therapy prior to surgical resection / start of oncological therapy the date of surgery / radiotherapy / chemotherapy should be recorded.

Insertion of intrauterine devices (IUDs) e.g. Mirena should not be considered as treatment.

For patients undergoing no active treatment (e.g. supportive care only) the date recorded should be the first date the decision was taken not to give the patient treatment as part of their primary therapy. Where this has subsequently been confirmed at MDT, the date of MDT should be recorded. This will be therefore be the same date recorded as for First Treatment Date.

If the exact date is not documented, record as 09/09/1900 (Not recorded).

If the patient died before treatment or the patient refused treatment, record as 10/10/1900 (Not applicable).

Related Data Item(s):

1 Total Hysterectomy/BSO, Total Hysterectomy/BSO and Lymphadenectomy (pelvic, aortic, pelvic and para-aortic, inguinal) or Subtotal Hysterectomy/BSO
Section 3: Surgery
Location Code {Cancer Surgery}

Common Name(s): Location, Location of Contact.


Definition: This is the reference number of any building or set of buildings where events pertinent to NHS Scotland take place. Locations include hospitals, health centres, GP surgeries, clinics, NHS board offices, nursing homes, schools and patient/client’s home.

Field Name: HOSPSURG
Field Type: Characters
Field Length: 5

Notes for Users: Required for national survival analysis and national comparative analysis.

This is the hospital of first definitive surgery which removes the primary tumour. This may be a planned excision even if close margins are found and further surgery is required. On occasion, this result will be achieved by excision biopsy. This should be included as site of first definitive surgery.

Each location has a location code, which is maintained jointly by PHS and General Register Office (Scotland). http://www.show.scot.nhs.uk/smrfiles/information.html – datafiles.

Location must be viewed as an address and not a code. If any new locations arise where NHS healthcare is delivered/administered, please ensure that the Reference Files Team at PHS is informed using form LOC-NEW (which can be downloaded from the website below) so that a new code may be issued as appropriate. http://www.show.scot.nhs.uk/smrfiles

Information about location should be electronically stored, managed and transferred using the relevant location code. IT systems should allow the recording and display of locations on the user interface as the relevant location name and associated address, etc.

If the location code is not documented, record as X9999.
If surgery has not been performed or the patient has refused surgery, record as not applicable, X1010.

Examples of codes are given below:

<table>
<thead>
<tr>
<th>Code</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>A111H</td>
<td>CROSSHOUSE HOSPITAL</td>
</tr>
<tr>
<td>C418H</td>
<td>ROYAL ALEXANDRA HOSPITAL</td>
</tr>
<tr>
<td>F704H</td>
<td>VICTORIA HOSPITAL, KIRKCALDY</td>
</tr>
<tr>
<td>G107H</td>
<td>GLASGOW ROYAL INFIRMARY</td>
</tr>
<tr>
<td>G405H</td>
<td>SOUTHERN GENERAL HOSPITAL, GLASGOW</td>
</tr>
</tbody>
</table>

**Related Data Item(s):**
Date of Surgery
**Date of Surgery**

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** This is the date the main (definitive) surgery was performed.

**Field Name:** SURGDATE  
**Field Type:** Date (DD/MM/CCYY).  
**Field Length:** 10

**Notes for Users:** Required for QPIs: 4, 7 and for national survival analysis / national comparative analysis.

This is the date of tumour resection and not the date of any diagnostic surgical procedures.

Note that if a lymphadenectomy is done at a later stage than the total hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO) then record the date the TAH/BSO was performed.

If the exact date of surgery is not known, record as 09/09/1900 (Not recorded).

If no surgery was performed, record as 10/10/1900 (Not applicable).

All treatments given as part of the initial treatment plan.

**Related Data Items:**  
Location Code {Cancer Surgery}
Surgery Performed

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** This denotes the surgical procedure performed for treatment of Endometrial Cancer.

**Field Name:** SURG  
**Field Type:** Integer  
**Field Length:** 2

**Notes for Users:** Required for QPIs: 3, 7

Note that if a lymphadenectomy is done at a later stage than the total hysterectomy and bilateral salpingo-oophorectomy then code “2” should be recorded to capture the complete operation.

Where a patient has undergone a previous bilateral salpingo-oophorectomy, the current surgery should be coded as either 1, 2 or 3 depending on the other elements of surgery performed.

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Total hysterectomy and bilateral salpingo-oophorectomy</td>
<td>Removal of the uterus, cervix, both fallopian tubes, and both ovaries.</td>
</tr>
<tr>
<td>2</td>
<td>Total hysterectomy, bilateral salpingo-oophorectomy and lymphadenectomy</td>
<td>Removal of pelvic nodes in addition to removal of the uterus, cervix, both fallopian tubes, and both ovaries.</td>
</tr>
<tr>
<td>3</td>
<td>Sub total hysterectomy and bilateral salpingo-oophorectomy</td>
<td>Removal of the uterus, both fallopian tubes, and both ovaries (cervix left in place).</td>
</tr>
<tr>
<td>4</td>
<td>Total hysterectomy</td>
<td>Removal of uterus and cervix</td>
</tr>
<tr>
<td>5</td>
<td>Total hysterectomy and lymphadenectomy</td>
<td>Removal of pelvic nodes in addition to removal of uterus and cervix.</td>
</tr>
<tr>
<td>6</td>
<td>Sub total hysterectomy</td>
<td>Removal of the uterus but the cervix is left in place.</td>
</tr>
<tr>
<td>94</td>
<td>Patient died before treatment</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Patient refused treatment</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>E.G. non-surgical patient.</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td>Evidence in patient record that surgery was received but details of the type of surgery is not recorded.</td>
</tr>
</tbody>
</table>

**Related Data Item(s):**  
Date of Surgery  
Surgical Approach
Surgical Approach

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** This is the method of surgical approach for the main (definitive) or only operation performed.

**Field Name:** SURGAPPR  
**Field Type:** Characters  
**Field Length:** 3

**Notes for Users:** Required for QPI: 4

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Open</td>
<td></td>
</tr>
<tr>
<td>2A</td>
<td>Laparoscopic</td>
<td></td>
</tr>
<tr>
<td>2B</td>
<td>Laparoscopic converted to open</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Vaginal Hysterectomy</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>E.g. non-surgical patient</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td>Evidence in patient record that surgery was undertaken but details of the type of surgery is not recorded</td>
</tr>
</tbody>
</table>

**Related Data Item(s):**  
Surgery Performed
Section 4: Pathological Details
Morphology of Tumour – Post-Operative

**Main Source of Data Item Standard:** Pathology and Genetics of Tumours of the Female Reproductive Organs’, WHO Histological Classification of Tumours 2007.

**Definition:** This is the morphology of the tumour according to the International Classification of Diseases for Oncology (ICD-O(3)) based on the operative procedure.

**Field Name:** MORPHOL
**Field Type:** Characters
**Field Length:** 6

**Notes for Users:** Required for QPI: 5

The morphology terms have five-digit code numbers which run from 8000/0 to 9989/1; the first four digits indicate the specific histologic terms and the fifth digit, after the slash, is a behaviour code.

If material supplied cannot be assessed code to ‘not assessable’ (1111/1).

If not recorded, record as 9999/9 (Not recorded).

If the pathology report is negative code to 8888/8. E.g. if a polyp is removed showing no residual disease.

If no invasive operative procedures were undertaken record as not applicable (1010/0).

Morphology codes are shown below. This list is not exhaustive and if a code is not on the list please contact - phs.canceraudit@phs.scot for advice.
Morphology codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>8010/3</td>
<td>Carcinoma, NOS, epithelial tumour, malignant</td>
</tr>
<tr>
<td>8020/3</td>
<td>Carcinoma, undifferentiated, NOS</td>
</tr>
<tr>
<td>8050/3</td>
<td>Papillary carcinoma, NOS</td>
</tr>
<tr>
<td>8070/3</td>
<td>Squamous cell carcinoma</td>
</tr>
<tr>
<td>8120/3</td>
<td>Transitional cell carcinoma</td>
</tr>
<tr>
<td>8140/3</td>
<td>Adenocarcinoma, NOS</td>
</tr>
<tr>
<td>8262/3</td>
<td>Villous adenocarcinoma</td>
</tr>
<tr>
<td>8310/3</td>
<td>Clear cell adenocarcinoma, clear cell carcinoma</td>
</tr>
<tr>
<td>8323/3</td>
<td>Mixed cell adenocarcinoma</td>
</tr>
<tr>
<td>8380/3</td>
<td>Endometrioid adenocarcinoma, endometrioid carcinoma, endometrioid cystadenocarcinoma</td>
</tr>
<tr>
<td>8382/3</td>
<td>Endometrioid adenocarcinoma, secretory variant</td>
</tr>
<tr>
<td>8383/3</td>
<td>Endometrioid adenocarcinoma, ciliated cell variant</td>
</tr>
<tr>
<td>8441/3</td>
<td>Serous cystadenocarcinoma, serous adenocarcinoma, serous carcinoma</td>
</tr>
<tr>
<td>8480/3</td>
<td>Mucinous adenocarcinoma</td>
</tr>
<tr>
<td>8481/3</td>
<td>Mucin-producing (or secreting) adenocarcinoma, mucin-producing (or secreting) carcinoma</td>
</tr>
<tr>
<td>8570/3</td>
<td>Endometrioid adenocarcinoma with squamous differentiation</td>
</tr>
<tr>
<td>8041/3</td>
<td>Small cell carcinoma</td>
</tr>
<tr>
<td>8560/3</td>
<td>Adenosquamous carcinoma</td>
</tr>
<tr>
<td>8980/3</td>
<td>Carcinosarcoma, NOS</td>
</tr>
<tr>
<td>8933/3</td>
<td>Adenosarcoma</td>
</tr>
<tr>
<td>1111/1</td>
<td>Not assessable</td>
</tr>
<tr>
<td>1010/0</td>
<td>Not applicable</td>
</tr>
<tr>
<td>8888/8</td>
<td>Negative Pathology</td>
</tr>
<tr>
<td>9999/9</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>

Related Data Items:
Final FIGO Stage {Endometrial Cancer}

Main Source of Data Item Standard: International Federation of Obstetricians and Gynaecologists (FIGO) Staging System – revision 2009

Definition: This denotes the final stage of disease as classified by the International Federation of Obstetricians and Gynaecologists for endometrial cancer.

Field Name: FIGO
Field Type: Characters
Field length:5

Notes for Users: Required for QPIs: 3, 5, 6

If stage is not documented in the pathology report or MDT do not deduce from other information and record as 'not recorded'.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Tumour contained to corpus uteri</td>
</tr>
<tr>
<td>IA</td>
<td>No or less than half myometrial invasion</td>
</tr>
<tr>
<td>IB</td>
<td>Invasion equal to or more than half of the myometrium</td>
</tr>
<tr>
<td>II</td>
<td>Tumour invades the cervical stroma but does not extend beyond the uterus</td>
</tr>
<tr>
<td>III</td>
<td>Local and/or regional spread of tumour</td>
</tr>
<tr>
<td>IIIA</td>
<td>Tumour invades the serosa of the corpus uteri and/or adnexas</td>
</tr>
<tr>
<td>IIIB</td>
<td>Vaginal and/or parametrial involvement</td>
</tr>
<tr>
<td>IIIC</td>
<td>Metastases to pelvis and/or para-aortic lymph nodes</td>
</tr>
<tr>
<td>IIIC1</td>
<td>- Positive pelvic nodes</td>
</tr>
<tr>
<td>IIIC2</td>
<td>- Positive para-aortic lymph nodes with or without positive pelvic lymph nodes</td>
</tr>
<tr>
<td>IV</td>
<td>Tumour invades into bladder and/or bowel mucosa and/or</td>
</tr>
<tr>
<td>IVA</td>
<td>Tumour invasion bladder and/or bowel</td>
</tr>
<tr>
<td>IVB</td>
<td>Distant metastases including intra-abdominal and/or inguinal lymph nodes</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>

Related Data Items:
Tumour Grade – Post Operative {Endometrial Cancer}

Main Source of Data Item Standard:

Definition: The pathological assessment of tumour differentiation used as a prognostic indicator. This is the tumour grade based on the operative procedure.

Field Name: TGRADE
Field Type: Characters
Field length: 4

Notes for Users: Required for QPI: 5

The pathology report should state grade as high, moderate or low. If there are mixed statements (e.g. low to moderate grade) record the worst situation (moderate in this example).

If grade is not documented do not deduce from other information and record as ‘not recorded’.

If no operative procedures were undertaken record as not applicable (96).

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>Grade 1 - Low Grade</td>
<td>Well differentiated</td>
</tr>
<tr>
<td>G2</td>
<td>Grade 2 - Moderate Grade</td>
<td>Moderately differentiated</td>
</tr>
<tr>
<td>G3</td>
<td>Grade 3 - High Grade</td>
<td>Poorly differentiated, undifferentiated</td>
</tr>
<tr>
<td>8888</td>
<td>Not assessable</td>
<td>Grade cannot be determined, e.g. specimen too poorly preserved or too small. Includes microinvasion.</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>e.g. no surgery performed</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Item(s):
Section 5: Oncology
Radiotherapy Course Type

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The type of course of external beam radiotherapy administered for the treatment of the cancer.

Field Name: RADIOTYPE
Field Type: Integer
Field length: 2

Notes for Users: Required for QPI: 5, and for national survival analysis / national comparative analysis.

Combined treatments may be administered concurrently/synchronously e.g. chemotherapy and radiotherapy, intra-operative radiotherapy.

For patients undergoing chemoradiotherapy the radiotherapy element should be recorded as code ‘06’ and recorded also in SACT under code ‘05’.

All treatments given as part of the initial treatment plan

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Adjuvant</td>
<td>It is given after potentially curative surgery.</td>
</tr>
<tr>
<td>2</td>
<td>Radical</td>
<td>It is primary treatment and is given with curative intent.</td>
</tr>
<tr>
<td>3</td>
<td>Palliative</td>
<td>The aim is solely to relieve symptoms.</td>
</tr>
<tr>
<td>4</td>
<td>Neo-adjuvant</td>
<td>It is given before potentially curative surgery.</td>
</tr>
<tr>
<td>6</td>
<td>Chemoradiotherapy</td>
<td>Radical radiotherapy given in combination with concurrent chemotherapy. Chemotherapy element of this combined treatment should be recorded separately in field ‘Type of Systemic Anti-Cancer Therapy (SACT) 1-2’</td>
</tr>
<tr>
<td>94</td>
<td>Patient died before radiotherapy treatment</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Patient refused radiotherapy treatment</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>e.g. no radiotherapy given.</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Items:
Date Treatment Started (Radiotherapy)
Date Treatment Completed (Radiotherapy)
Date Treatment Started (Radiotherapy)

Main Source of Data Item Standard: The National Audit Cancer Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date cancer treatment course commenced.

Field Name: RSTARTDATE
Field Type: Date (DD/MM/CCYY)
Field length: 10

Notes for Users: Required for national survival analysis and national comparative analysis.

This is the first fraction of a course of radiotherapy.

For the purposes of national audit, only radiotherapy given as part of the primary treatment plan should be recorded. Palliative radiotherapy to other (metastatic) sites is only recorded if part of the initial treatment plan.

If the date radiotherapy started is unknown, record as 09/09/1900 (Not recorded).

If radiotherapy has not been given or the patient has refused radiotherapy, record as 10/10/1900 (not applicable).

Related Data Items:
Radiotherapy Course Type
Date Treatment Completed (Radiotherapy)
Date Treatment Completed (Radiotherapy)

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date cancer treatment course ended.

Field Name: RCOMPDATE
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users: Required for national survival analysis and national comparative analysis.

This is the last fraction of a course of radiotherapy.

It should be noted this can be the same day as the day the therapy started.

If the date treatment completed is unknown, record as 09/09/1900 (Not recorded).

If treatment has not been given, record as 10/10/1900 (not applicable).

Related Data Item(s):
Radiotherapy Course Type
Date Treatment Started (Radiotherapy)
Vaginal Vault Brachytherapy {Endometrial Cancer}

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** Denoted where the patient had Vaginal Vault Brachytherapy

**Field Name:** BRACHY  
**Field Type:** Integer  
**Field Length:** 2

**Notes for Users:** Required for QPI: 5

For the purposes of national audit, only brachytherapy given as part of the primary treatment plan should be recorded.

If unknown, record as 99 (Not recorded).

**Code and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>No</td>
</tr>
<tr>
<td>95</td>
<td>Patient refused treatment</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>

**Related Data Item(s):**  
Radiotherapy Course Type  
Date Treatment Started (Radiotherapy)
Type of Systemic Anti-Cancer Therapy (SACT) 1-2

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The type of course of cytotoxic or biological drugs administered for the treatment of the cancer. Cytotoxic drugs are drugs which destroy cells.

Field Name: CHEMTYPE1  
CHEMTYPE2
Field Type: Integer
Field Length: 2

Notes for Users: Required for QPIs: 3, 6

Patients may have ongoing systemic therapy both before and after surgery. These patients should be recorded under neo-adjuvant Type. Some patients may have separate completion chemotherapy post-operatively. This may be recorded as two courses neo-adjuvant and adjuvant.

Systemic therapy must be treatment received for initial management and not treatment for recurrence or relapse.

For patients undergoing chemoradiotherapy the chemotherapy element should be recorded as code ‘05’ and recorded also in ‘Radiotherapy Course Type’ under code ‘06’.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Neoadjuvant</td>
<td>Therapy given prior to radiotherapy or first definitive surgery to reduce tumour size.</td>
</tr>
<tr>
<td>2</td>
<td>Adjuvant</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Palliative</td>
<td>Systemic therapy given for symptom control without curative intent e.g. for patients with metastatic disease at time of diagnosis.</td>
</tr>
<tr>
<td>5</td>
<td>Chemoradiotherapy</td>
<td>Concurrent radiotherapy element of this combined treatment should be recorded separately in field ‘Radiotherapy Course Type’</td>
</tr>
<tr>
<td>7</td>
<td>Biological Therapy</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Hormone Therapy</td>
<td>E.g. oral progestin, letrozole</td>
</tr>
<tr>
<td>94</td>
<td>Patient died before SACT treatment</td>
<td>i.e. Patient who died before receiving planned SACT treatment</td>
</tr>
<tr>
<td>95</td>
<td>Patient refused SACT treatment</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>e.g. Systemic therapy not given as primary part of therapy.</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Date Treatment
Completed Systemic Anti-Cancer Therapy (SACT) {Cancer} 1-2
**Date Treatment Started Systemic Anti-Cancer Therapy (SACT) {Cancer} 1-2**

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The date cancer treatment course commenced.

**Field Name:** CHEMDATE1

**CHEMDATE2**

**Field Type:** Date (DD/MM/CCYY)

**Field length:** 10

**Notes for Users:** Required for national survival analysis and national comparative analysis.

This is the first dose of the first cycle of a course of chemotherapy or biological therapy.

If the date SACT started is unknown, record as 09/09/1900 (Not recorded).

If SACT has not been given or the patient has refused SACT, record as 10/10/1900 (not applicable).

**Related data items:**

Type of Systemic Anti-Cancer Therapy (SACT) 1-2

Date Treatment Completed Systemic Anti-Cancer Therapy (SACT) {Cancer} 1-2
Date Treatment Completed Systemic Anti-Cancer Therapy (SACT) {Cancer} 1-2

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date cancer treatment course ended.

Field Name: CHEMENDATE1
            CHEMENDATE2
Field Type: Date (DD/MM/CCYY)
Field length: 10

Notes for Users: Required for national survival analysis and national comparative analysis.

This is the first day of the last cycle of a course of chemotherapy, or biological therapy.

It should be noted this can be the same day as the day the therapy started.

If the date treatment started is unknown, record as 09/09/1900 (Not recorded).

If SACT has not been given or the patient has refused SACT, record as 10/10/1900 (Not applicable).

Codes and values:

Related data items:
Type of Systemic Anti-Cancer Therapy (SACT) 1-2
Section 6: Clinical Trials
Patient Entered into Clinical Trial

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: An indication of whether or not the patient received treatment within the context of a clinical trial.

Field Name: TRIAL
Field Type: Integer
Field Length: 2

Notes for Users: Required for generic QPIs.

This relates only to participation in clinical trials which may be national or international multi-centred trials.

The majority of non-commercial multi-centred trials available in Scotland are NCRN badged or equivalent.

Some academic and university units may have ongoing local trials which should not be included here. These can be recorded on local trials databases.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>No</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>
Section 7: Death Details
Date of Death

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:**
This is the certified date of death as recorded by the General Register Office (Scotland) (GRO(S)).

**Field Name:** DOD
**Field Type:** Date (DD/MM/CCYY).
**Field Length:** 10

**Notes for Users:** Required for QPI: 7 and for national survival analysis / national comparative analysis.

If the exact date is not documented, record as 09/09/1900 (Not recorded).

If the patient is alive use the code 10/10/1900 (Not applicable).